TY - JOUR
T1 - Diuretic response in acute heart failure - An analysis from ASCEND-HF
AU - Ter Maaten, Jozine M.
AU - Dunning, Allison M.
AU - Valente, Mattia A.E.
AU - Damman, Kevin
AU - Ezekowitz, Justin A.
AU - Califf, Robert M.
AU - Starling, Randall C.
AU - Van Der Meer, Peter
AU - O'Connor, Christopher M.
AU - Schulte, Phillip J.
AU - Testani, Jeffrey M.
AU - Hernandez, Adrian F.
AU - Tang, W. H.Wilson
AU - Voors, Adriaan A.
N1 - Funding Information:
A total of 7,141 patients were enrolled in the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure trial (ASCEND-HF), a randomized, double-blind, placebo-controlled trial with neutral results. The study design and main results have been published previously. 10 The trial was approved by each participating center’s ethics committee, and all participants provided written informed consent (ClinicalTrials.gov no: NCT00475852). Patient characteristics were recorded at baseline. Weight was measured daily. Blood pressure, creatinine, and blood urea nitrogen (BUN) were measured at baseline, at 24 hours, and at discharge or 10 days after admission. Urine output was collected during the first 24 hours. Fluid intake was not registered. To correct for biological availability, total diuretic dose was defined as intravenous dose plus 0.5 × oral dose from randomization through 24 hours. Diuretic response was defined as weight change from hospital admission to 48 hours per 40 mg of furosemide (or equivalent) administered through the first 24 hours. As an additional analysis, a novel diuretic response metric was investigated using urine volume from hospital admission to 24 hours per 40 mg of furosemide (or equivalent) administered from qualifying event to randomization. The ASCEND-HF trial was supported by Scios Inc, and this work was supported internally by the Duke Clinical Research Institute.
Publisher Copyright:
© 2015 Elsevier Inc. All rights reserved.
PY - 2015/8/1
Y1 - 2015/8/1
N2 - Background Diuretic unresponsiveness often occurs during hospital admission for acute heart failure (AHF) and is associated with adverse outcome. This study aims to investigate determinants, clinical outcome, and the effects of nesiritide on diuretic response early after admission for AHF. Methods Diuretic response, defined as weight loss per 40 mg of furosemide or equivalent, was examined from hospital admission to 48 hours in 4,379 patients from the ASCEND-HF trial. As an additional analysis, a urinary diuretic response metric was investigated in 5,268 patients using urine volume from hospital admission to 24 hours per 40 mg of furosemide or equivalent. Results Mean diuretic response was -0.42 kg/40 mg of furosemide (interquartile range -1.0, -0.05). Poor responders had lower blood pressure, more frequent diabetes, long-term use of loop diuretics, poorer baseline renal function, and lower urine output (all P <.01). Randomized nesiritide treatment was not associated with diuretic response (P =.987). Good diuretic response was independently associated with a significantly decreased risk of 30-day all-cause mortality or heart failure rehospitalization (odds ratio 0.44, 95% CI 0.29-0.65, highest vs lowest quintile, P <.001). Diuretic response based on urine output per 40 mg of furosemide showed similar results in terms of clinical predictors, association with outcome, and the absence of an effect of nesiritide. Conclusions Poor diuretic response early after hospital admission for AHF is associated with low blood pressure, renal impairment, low urine output, and an increased risk of death or rehospitalization early after discharge. Nesiritide had a neutral effect on diuretic response.
AB - Background Diuretic unresponsiveness often occurs during hospital admission for acute heart failure (AHF) and is associated with adverse outcome. This study aims to investigate determinants, clinical outcome, and the effects of nesiritide on diuretic response early after admission for AHF. Methods Diuretic response, defined as weight loss per 40 mg of furosemide or equivalent, was examined from hospital admission to 48 hours in 4,379 patients from the ASCEND-HF trial. As an additional analysis, a urinary diuretic response metric was investigated in 5,268 patients using urine volume from hospital admission to 24 hours per 40 mg of furosemide or equivalent. Results Mean diuretic response was -0.42 kg/40 mg of furosemide (interquartile range -1.0, -0.05). Poor responders had lower blood pressure, more frequent diabetes, long-term use of loop diuretics, poorer baseline renal function, and lower urine output (all P <.01). Randomized nesiritide treatment was not associated with diuretic response (P =.987). Good diuretic response was independently associated with a significantly decreased risk of 30-day all-cause mortality or heart failure rehospitalization (odds ratio 0.44, 95% CI 0.29-0.65, highest vs lowest quintile, P <.001). Diuretic response based on urine output per 40 mg of furosemide showed similar results in terms of clinical predictors, association with outcome, and the absence of an effect of nesiritide. Conclusions Poor diuretic response early after hospital admission for AHF is associated with low blood pressure, renal impairment, low urine output, and an increased risk of death or rehospitalization early after discharge. Nesiritide had a neutral effect on diuretic response.
UR - http://www.scopus.com/inward/record.url?scp=84939568411&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84939568411&partnerID=8YFLogxK
U2 - 10.1016/j.ahj.2015.05.003
DO - 10.1016/j.ahj.2015.05.003
M3 - Article
C2 - 26299229
AN - SCOPUS:84939568411
SN - 0002-8703
VL - 170
SP - 313-321.e4
JO - American Heart Journal
JF - American Heart Journal
IS - 2
ER -